BRCA2 and neoplasm: Many of the preclinical, non-reversion mechanisms of resistance described in the literature are specific to BRCA1, for example loss of expression of the Shieldin complex26,40, therefore it may be that tumours associated with BRCA2 alterations have fewer pathways to resistance and therefore reversions predominate.